[ad_1]
The first coronavirus drug to contain the active ingredient remdesivir, developed by the pharmaceutical company Richter Gedeon Nyrt., Is the first in Hungary to be used at the University of Debrecen. Infusion therapy that inhibits viral growth is being administered to seriously ill patients in a clinical trial that has just begun, the university’s press office told MTI on Tuesday.
It was written that the research team working in DE’s Department of Infectious Diseases was the first in Hungary to use the Hungarian remdesivir developed and manufactured by the university’s strategic partner, Richter.
Several patients have already received the infusion treatment on Monday, after the director of the university’s coordinating center for drug development, Dénes Páll, signed the research contract. More seriously ill patients who require long-term oxygen support and who meet the inclusion criteria have the option of using infusion therapy.
According to the announcement, István Várkonyi, head of the Debrecen research group and acting director of the Infectious Diseases Clinic, noted that it had previously been confirmed by clinical trials that remdesivir
- shortens the time spent in the hospital,
- reduces oxygen demand,
- accelerates the healing time of lung damage,
- and it can reduce the number of patients who need a ventilator.
It is expected to have the same effect in seriously ill patients, he added.
He noted that in addition to the four medical training universities and the two national institutes, the Korányi Pulmonology Institute and the South Pest Central Hospital, the designated Covid hospitals are participating in the current clinical trial.
Medical training universities and national institutes have been cooperating for months with government support in the testing of various antiviral drugs, including Avigan, which was also used for the first time in the national clinical trial in Debrecen, and Hungarian-made favipiravir . The aim is to make all effective treatments available to the Hungarian population. – István Várkonyi expressed.
The Hungarian-made product containing remdesivir, which can be administered as an infusion, is used in seriously ill national patients for five days in the national clinical trial, the expert said.
[ad_2]
